MEDINCELL Shares Drop 3.64% at Close, Pausing After a Stellar Quarter
The share price of the Montpellier-based biotech company MEDINCELL fell by 3.64% on Thursday, November 27, closing at 28.06 euros compared to 29.12 euros the previous day. Despite this decline, the stock's performance remains impressive over the past few months, with a surge of 61.73% over three months and 55.2% over a year, significantly outperforming the CAC 40.
Recent Developments and Market Adjustments
MEDINCELL announced on Monday, November 25, that it had received a $3 million grant from the Gates Foundation for its mdc-STM malaria program, a development that did not prevent the stock from continuing its adjustment. Thursday's decline brings the weekly loss to 6.03%, a consolidation phase expected after the sharp rise in recent weeks. The company was selected at the beginning of November to join the MSCI World Small Cap index, an event that also supported the stock's trajectory. However, volatility remains high at 17.06 over a month, with modest trading volumes of 0.19% of capital this Thursday, confirming the narrow liquidity of the stock. The recent context is marked by concerns that emerged at the beginning of November regarding sequential sales of UZEDY, the schizophrenia treatment marketed by partner Teva Pharmaceuticals. Sales of the product had increased by 24% year-on-year in the third quarter to $43 million but had fallen by 20.37% compared to the second quarter. This dynamic had triggered a correction over several sessions in mid-November, weighing on investor confidence despite the development prospects of the BEPO technology platform. The Paris market, meanwhile, showed a slight increase of 0.04% in the session.
Technical Analysis Highlights Vulnerabilities
Technical analysis highlights a vulnerability zone for MEDINCELL's stock. The price of 28.06 euros is now very close to the support threshold identified at 28.12 euros, a level that could prove crucial in the short term. The 50-day moving average is at 30.00 euros, about 7% above the current price, indicating a weakening of the recent bullish momentum. The difference with the 200-day moving average, positioned at 19.33 euros, nevertheless illustrates the significant progress of the stock since the beginning of the year. Bollinger Bands frame the price between 25.09 euros and 38.19 euros, indicating significant volatility amplitude. The Relative Strength Index at 32 signals a technical oversold zone, suggesting that the decline may be nearing its end in the short term. This level reflects a potential exhaustion of selling pressure after several sessions of decline. The negative MACD at -1.17, below its signal line at -0.77, however, confirms the weakness of the short-term trend. The Cash Money Flow at -0.20 also indicates a capital outflow over the recent period, consistent with the observed consolidation phase. These indicators argue for continued caution, as the stock must reclaim its 50-day moving average to validate a bullish reversal.
Sectoral Outlook and Strategic Positioning
Sectorally, MEDINCELL benefits from a unique positioning in the segment of long-acting injectable drugs, with its proprietary BEPO technology allowing controlled release over several weeks or months. The commercial prospects are primarily based on royalties from sales of UZEDY by Teva, with the U.S. market representing a major growth relay for the coming years. The recent inclusion in the MSCI World Small Cap index should enhance the group's visibility among international institutional investors, contributing to the gradual broadening of the shareholder base. The stock has a negative beta of -0.09, illustrating an unusual decorrelation with the movements of the Paris market. This characteristic reflects the speculative nature of the stock, whose evolution depends more on internal catalysts than on macroeconomic trends. Resistance levels to watch are now at 38.46 euros, nearly 37% above the current price. After a year 2025 marked by extreme volatility and spectacular performances, MEDINCELL is going through a phase of questioning about the ability of its partner Teva to accelerate UZEDY sales. Investors are now waiting for more tangible elements on the commercial trajectory of the product in the fourth quarter to validate or not the current valuation.
